摘要
目的探讨可溶性血管内皮生长因子受体1(sFlt-1)和胎盘生长因子(PlGF)水平及其比值的变化与围产儿结局的相关性。方法选取2018年4月至2019年5月在本院定期产检并最终分娩的孕24~36周存在子痫前期及子痫前期高危因素孕妇为研究对象(115例),计算sFlt-1/PlGF比值,根据sFlt-1/PlGF比值(<38、38~85和>85)将患者分为3组。结果SFlt-1/PlGF>85组围产儿结局不良,主要表现为新生儿体重低、分娩孕周小,sFlt-1/PlGF比值与围产儿结局之间差异存在显著的统计学意义(P<0.001)。结论SFlt-1/PlGF比值>85提示子痫前期或其他胎盘功能障碍,这与新生儿体重降低和早产有关。对妊娠合并胎盘功能障碍的孕妇进行血管生成标志物的检测和sFlt-1/PlGF比值的计算,有助于更好地诊断、治疗,从而改善围产儿结局。
Objective Soluble fms-like tyrosine kinase-1(sFlt-1)and placental growth factor(PlGF)are used as markers of preeclampsia.The aim of this study was to assess the correlations between the sFlt-1/PlGF ratio values within the<38,38-85 and>85 brackets and perinatal outcomes in pregnancies that required the determination of these markers.Methods A total of 115 pregnant patients between 24 and 36 weeks’gestation suspected of or confirmed with preeclampsia were included in the study.In each of the patient,the sFlt-1/PlGF ratio was calculated.All patients were divided into three groups according to the sFlt-1/PlGF ratio as following:<38,38-85 or>85.Results Significantly worse perinatal outcomes were observed in the sFlt-1/PlGF>85 group,primarily with lower neonatal birth weight and shorter duration of gestation.Statistically significant correlations between the values of these markers and the abovementioned perinatal effects were identified.Conclusion An sFlt-1/PlGF ratio value of>85 suggests that either preeclampsia or one of the other placental insufficiency forms may occur,which is associated with a lower newborn weight and earlier delivery.Determining the disordered angiogenesis markers and calculating the sFlt-1/PlGF ratio in pregnancies complicated by placental insufficiency may lead to a better diagnosis,therapeutic decision and better perinatal outcomes.
作者
赵晟隆
刘晓巍
刘静
田玉翠
ZHAO Shenglong;LIU Xiaowei;LIU Jing;TIAN Yucui(Department of Perinatal Medicine,Beijing Obstetrics and Gynecology Hospital,Capital Medical University,Beijing 100043,China)
出处
《标记免疫分析与临床》
CAS
2020年第12期2035-2039,共5页
Labeled Immunoassays and Clinical Medicine
基金
首都医科大学附属北京妇产医院院内课题(编号:FCYYGL201813)。